Literature DB >> 11299573

Examination of the lower limb in high risk patients.

D Santos1, T Carline.   

Abstract

When 'at risk' patients say that their feet are killing them, they may be right. Diabetes mellitus accounts for 50 to 70% of all nontraumatic amputations with a three year survival rate of those who undergo a lower limb amputation of 50%. Furthermore, when compared to the 'normal' foot, the 'at risk' foot is more likely to develop complications, thus it is vital to identify such 'at risk' individuals in an attempt to prevent the risk of deformity, ulceration, infection and/or necrosis/gangrene. The assessment involves history taking, the examination and further investigations, providing the necessary information to make a clinical diagnosis and identify 'at risk' groups. During the examination the foot-wear should be checked, nails and skin condition should be closely inspected and tests should be carried out for signs of peripheral neuropathy, ischaemia and venous/lymphatic deficiency. Other complications like deformity and increases in foot pressure may cause ulceration. Where ulcers are present, an in-depth systematic inspection is necessary. A thorough lower limb examination of high risk patients provides the necessary information to make a clinical diagnosis and plan preventative measures to avoid future complications.

Entities:  

Mesh:

Year:  2000        PMID: 11299573     DOI: 10.1016/s0965-206x(00)80037-6

Source DB:  PubMed          Journal:  J Tissue Viability        ISSN: 0965-206X            Impact factor:   2.932


  2 in total

Review 1.  Diagnosis and management of diabetic neuropathy.

Authors:  Bruce A Perkins; Vera Bril
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

2.  Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections.

Authors:  Fermín R Martínez-De Jesús; Antonio Ramos-De la Medina; José María Remes-Troche; David G Armstrong; Stephanie C Wu; Jose Luis Lázaro Martínez; Juan V Beneit-Montesinos
Journal:  Int Wound J       Date:  2007-10-22       Impact factor: 3.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.